Lung Cancer
Volume 70, Issue 2 , Pages 188-194, November 2010

Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer

  • Soo-Jung Um

      Affiliations

    • Department of Internal Medicine, Dong-A University College of Medicine, 3-Ga Dongdaeshin-dong, Seo-gu, Busan 602-715, Republic of Korea
    • Both these authors contributed equally to this paper.
  • ,
  • Young Jin Choi

      Affiliations

    • Department of Internal Medicine, Pusan National University School of Medicine, Ami-dong, Seo-gu, Busan, Republic of Korea
  • ,
  • Ho-Jin Shin

      Affiliations

    • Department of Internal Medicine, Pusan National University School of Medicine, Ami-dong, Seo-gu, Busan, Republic of Korea
  • ,
  • Cheol Hun Son

      Affiliations

    • Binex Research Institute, Binex Co. Ltd., Busan, Republic of Korea
  • ,
  • You-Soo Park

      Affiliations

    • Binex Research Institute, Binex Co. Ltd., Busan, Republic of Korea
  • ,
  • Mee Sook Roh

      Affiliations

    • Department of Pathology, Dong-A University College of Medicine, Busan, Republic of Korea
  • ,
  • Yun Seong Kim

      Affiliations

    • Department of Internal Medicine, Pusan National University School of Medicine, Ami-dong, Seo-gu, Busan, Republic of Korea
  • ,
  • Young Dae Kim

      Affiliations

    • Department of Thoracic Surgery, Pusan National University School of Medicine, Busan, Republic of Korea
  • ,
  • Soo-Keol Lee

      Affiliations

    • Department of Internal Medicine, Dong-A University College of Medicine, 3-Ga Dongdaeshin-dong, Seo-gu, Busan 602-715, Republic of Korea
  • ,
  • Min Ho Jung

      Affiliations

    • Department of Microbiology, Dong-A University College of Medicine, Busan, Republic of Korea
  • ,
  • Min Ki Lee

      Affiliations

    • Department of Internal Medicine, Pusan National University School of Medicine, Ami-dong, Seo-gu, Busan, Republic of Korea
    • Both these authors contributed equally to this paper.
  • ,
  • Choonhee Son

      Affiliations

    • Department of Internal Medicine, Dong-A University College of Medicine, 3-Ga Dongdaeshin-dong, Seo-gu, Busan 602-715, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 51 240 2874; fax: +82 51 242 5852.
  • ,
  • Pil Jo Choi

      Affiliations

    • Department of Thoracic and Cardio-vascular Surgery, Dong-A University College of Medicine, Busan, Republic of Korea
  • ,
  • Jooseop Chung

      Affiliations

    • Department of Internal Medicine, Pusan National University School of Medicine, Ami-dong, Seo-gu, Busan, Republic of Korea
    • Corresponding Author InformationCo-corresponding author.
  • ,
  • Chi-Dug Kang

      Affiliations

    • Department of Biochemistry, Pusan National University School of Medicine, Busan, Republic of Korea
  • ,
  • Eun-Yup Lee

      Affiliations

    • Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Republic of Korea

Received 16 October 2009; received in revised form 8 February 2010; accepted 9 February 2010. published online 11 March 2010.

Abstract 

Background

A dendritic cell vaccine has been developed as a novel strategy for generating antitumor immunity in the treatment of cancer. The purpose of this study was to assess the maximal tolerated dose, safety, and immunologic response of a new dendritic cell vaccine (DC-Vac) into which tumor lysate was loaded by electroporation and pulse in patients with advanced non-small cell lung cancer (NSCLC).

Patients and methods

Fifteen patients with inoperable stage III or IV NSCLC were assigned to cohorts that received 3, 6, or 12×106 DC-Vac intradermally 3 times at 2 week intervals. We also evaluated immunologic and tumor responses.

Results

The maximum dose of DC-Vac (12×106) was shown to be safe. In 5 of 9 patients, the vaccine resulted in increased interferon (IFN)-γ production by CD8+ cells after exposure to tumor lysate. Additionally, there were mixed responses which do fulfill progressive disease definition but demonstrate some clinical benefit in two patients.

Conclusion

The administration of tumor lysate-loaded autologous dendritic cells by electroporation and pulse was non-toxic and induced immunologic responses to tumor antigens. The two mixed tumor responses which were achieved may represent a potential benefit of this new DC-Vac.

Keywords: Dendritic cells, Electroporation, Immunotherapy, Non-small cell lung carcinoma, Tumor vaccines

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(10)00071-1

doi:10.1016/j.lungcan.2010.02.006

Lung Cancer
Volume 70, Issue 2 , Pages 188-194, November 2010